Harrow, Inc. $HROW Shares Sold by LJI Wealth Management LLC

LJI Wealth Management LLC lessened its position in Harrow, Inc. (NASDAQ:HROW) by 49.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 15,300 shares of the company’s stock after selling 14,700 shares during the period. LJI Wealth Management LLC’s holdings in Harrow were worth $750,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Harrow in the second quarter valued at approximately $48,000. SBI Securities Co. Ltd. raised its position in shares of Harrow by 393.5% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after buying an additional 846 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Harrow in the third quarter valued at approximately $83,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Harrow by 25.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after buying an additional 369 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Ratings Changes

HROW has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Harrow in a research note on Thursday, March 19th. Cantor Fitzgerald dropped their target price on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Weiss Ratings lowered Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Finally, B. Riley Financial reiterated a “buy” rating and issued a $65.00 target price (down from $74.00) on shares of Harrow in a research note on Tuesday, April 7th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $69.86.

Harrow Stock Performance

Shares of HROW stock opened at $38.23 on Friday. Harrow, Inc. has a one year low of $21.12 and a one year high of $54.85. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The company has a 50 day moving average price of $38.43 and a 200 day moving average price of $42.44. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -224.87 and a beta of 0.34.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.